Today, a Director at Acorda Therapeutics (ACOR), Lorin Randall, sold shares of ACOR for $38.02K.
See today’s analyst top recommended stocks >>
Based on Acorda Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $143 million and GAAP net loss of $13.91 million. In comparison, last year the company earned revenue of $141 million and had a GAAP net loss of $25.2 million. Currently, Acorda Therapeutics has an average volume of 421.3K.
Based on 9 analyst ratings, the analyst consensus is Hold with an average price target of $23.63, reflecting a 18.9% upside.
The insider sentiment on Acorda Therapeutics has been negative according to 59 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.
